Month: September 2020

Opioid drug manufacturer Mallinckrodt PLC may seek Chapter 11 bankruptcy protection as the latest casualty in the nationwide opioid crisis. According to a recent article by Bloomberg, the company is working with external advisers, creditors and litigation claimants and is considering all options to address legal and financial challenges. The bankruptcy filing is expected to …

Opioid Manufacturer Mallinckrodt Heading Towards Bankruptcy Read More »

Overview of BSA Chapter 11 Bankruptcy On February 18, 2020, the national organization of the Boy Scouts of America (the BSA) filed a voluntary petition for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. The bankruptcy proceeding involves the Boy Scouts of America which is a national organization. The local …

Rampant Sexual Abuse Forces Boy Scout Bankruptcy Read More »

Last week a New York woman filed suit in federal court against Teva Pharmaceuticals after sustaining serious injuries when a ParaGard IUD broke apart when being removed by her doctor. Vanesha Johnson was forced to undergo unplanned surgery to have the broken arm of the birth control device removed, but unlike many victims, did not …

Teva Hit With Another Lawsuit Over Broken ParaGard IUD Read More »

Prior to being recalled in early 2020, Zantac was one of the most widely used medications for the treatment of heartburn, acid reflux and acid related digestive issues. Chemically known as ranitidine hydrochloride, Zantac (or ranitidine) is a class of drugs called histamine H2-receptor antagonists (H2 blockers), which decrease the body’s production of stomach acid, …

Zantac Litigation: What you need to know Read More »

What is Valsartan? Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs) and is used to treat high blood pressure and heart failure. Doctors commonly prescribe valsartan to people who have suffered from a heart attack or have type II diabetes. Valsartan is the generic version of the drug Diovan which is …

Valsartan: Too Many Recalls to Count Read More »